• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

    41.96 +0.74 (+1.80%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Roche Holding AG Basel American Depositary Shares

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
    Sangamo Therapeutics regains rights to its hemophilia A gene therapy as Pfizer ends their collaboration. The program showed positive Phase 3 results. 
    Via Benzinga
    Roche CEO Reassures No Job Cuts Despite Challenges: Report
    Roche Holding AG reportedly says no layoffs planned. CEO Schinecker provides pipeline updates including potential anti-obesity drug by 2029. 
    Via Benzinga
    Topics Workforce
    Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
    The drug technically missed the study's primary goal. But there's still promise it could work in specific patients. 
    Via Investor's Business Daily
    Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
    Prothena and Roche report Phase 2b PADOVA results on prasinezumab in Parkinson's, showing promising trends and nominal significance in key analyses. 
    Via Benzinga
    Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
    From Genentech
    Via Business Wire
    Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
    Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
    Via Benzinga
    Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
    Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments. 
    Via Investor's Business Daily
    Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
    The weight-loss drugs space continues to heat up. Here's the latest news from the segment. 
    Via Investor's Business Daily
    United Kingdom's National Health Service Drug Spending Priorities Questioned in New Analysis
    An analysis of NICE-approved drugs from 2000–2020 reveals trade-offs in NHS resource allocation, with high costs leading to a net loss of population health gains. 
    Via Benzinga
    New and Updated Data for Genentech’s Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
    From Genentech
    Via Business Wire
    Five-Year Results Confirm Genentech’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
    From Genentech
    Via Business Wire
    The Intersection of AI, Medicine, and Stocks: A New Era of Opportunities
    EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:AMZN),(NASDAQ:MDAI),(NYSE:MDT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    FDA Accepts Supplemental Biologics License Application for Genentech’s Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    From Genentech
    Via Business Wire
    Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
    EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    Avant Technologies’ Partner, Ainnova, Signs Pilot Program with Roche to Combat Diabetic Retinopathy
    Las Vegas, NV – December 4, 2024 – Avant Technologies, Inc.’s (OTCQB: AVAI) (“Avant” or the “Company”), partner, Ainnova Tech, Inc., (Ainnova) a leading healthcare technology company focused on... 
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    NVIDIA Invested in These 2 AI Stocks, Should You?
    Discover 2 compelling AI stocks NVIDIA (NASDAQ: NVDA) has invested in. Learn how the AI leader's vision can guide your portfolio in the tech revolution. 
    Via MarketBeat
    Topics Artificial Intelligence
    Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
    Outlook Therapeutics reports ONS-5010 missed noninferiority endpoint in NORSE EIGHT trial for wet AMD but showed vision improvement and safety profile. 
    Via Benzinga
    Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
    Roche agrees to acquire Poseida Therapeutics for $1.5 billion, expanding its CAR-T therapy platform with a focus on hematologic malignancies and solid tumors. 
    Via Benzinga
    Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
    From Genentech
    Via Business Wire
    Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry?
    Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints. 
    Via Investor's Business Daily
    Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
    CDTX sold its Rezayo business to concentrate on its MDC-producing Cloudbreak platform which has already produced several promising drug candidates, like CD388, a very promising clinical-stage... 
    Via Talk Markets
    Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
    The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
    Via Benzinga
    Genentech to Present New and Encouraging Long-term Follow-up Data Across Broad Hematology Portfolio at ASH 2024
    From Genentech
    Via Business Wire
    New England Journal of Medicine Publishes Landmark Phase III Results for Genentech’s Itovebi, Showing More Than Doubling of Progression-Free Survival in Certain Type of HR-Positive Advanced Breast Cancer
    From Genentech
    Via Business Wire
    Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
     
    Via Benzinga
    Biotech Momentum Trades For The Q4 Rally
    The biotech sector made an interim peak in late February followed by an active summer in very choppy trading. 
    Via Talk Markets
    Stock Market Mixed But Nasdaq Hits Record High As Tesla Leads Earnings Winners: Weekly Review
    The major indexes were mixed for the week. 
    Via Investor's Business Daily
    Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition
    Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition. 
    Via Benzinga
    Roche Retains Outlook After Two Out Of Three Big Hitters Top Sales Expectations
    The Swiss drugmaker kept its outlook for the year despite a third-quarter sales miss. 
    Via Investor's Business Daily
    Can Roche Challenge Lilly and Novo in the Weight Loss Market?
    One Wall Street analysts recently singled out a drug from pharma company Roche as a threat to Eli Lilly's oral GLP-1 candidate. 
    Via MarketBeat
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    33 34 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.